Net Loss Per Share Attributable to Common Stockholders (Tables)

9 Months Ended

Sep. 30, 2020

Earnings Per Share [Abstract]

Weighted-Average Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share as They Had Anti-Dilutive Effect

The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share for the periods presented as they had an anti-dilutive effect:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Options to purchase common stock		850,716		604,599		742,797		527,573
Contingently issuable common stock upon exchange of    Vaccinex Products, LP units		1,163,141		1,198,111		1,170,047		1,199,906
Contingently issuable common stock upon exchange of    VX3 units		1,318,797		1,318,797		1,318,797		1,318,797